

Inside this issue: Subsidy Changes

CareLink Subsidy Changes

1. Acetazolamide (Diamox® equivalent) capsules/tablets – CareLink will subsidize acetazolamide tablets/capsules without restrictions.
2. Codeine 10 mg/guaifenesin 100 mg (per 5 mL) cough syrups -CareLink will subsidize codeine/guaifenesin syrup according to P & T policy. Per P & T , use is limited to FDA-approved dosing. Prescriptions should be limited to one 120 mL bottle with no refills.
3. Codeine 10 mg/promethazine 6.25 mg (per 5 mL) cough syrups -CareLink will subsidize codeine/promethazine syrup according to P & T policy. Per P & T , use is limited to FDA-approved dosing. Prescriptions should be limited to one 120 mL bottle with no refills.
4. Dextroamphetamine (Dexedrine®) immediate-release tablets- Dextroamphetamine tablets have been removed from the UHS formulary.
5. Dextroamphetamine/amphetamine mixed salts (Adderall XR®): Adderall XR® was removed from the UHS formulary and will no longer be available. Lisdexamfetamine was added to replace Adderall XR®, however, the standard release also remains on the formulary.
6. Lisdexamfetamine (Vyvanse™) capsules- CareLink will not subsidize lisdexamfetamine, however the product is available through a medication assistance program (MAP). MAP eligible patients will receive prescription cards valid at external retail pharmacies; applications may take up to one month to process. Prescriptions may only be filled one time per month and reapplication to the program is required every six months. A \$5 co-payment is required at each dispensing.
7. Methazolamide (Neptazane® equivalent) tablets– CareLink will subsidize methazolamide tablets without restrictions.
8. Pancrelipase (Ultrase®) capsules -CareLink will subsidize Ultrase® without restrictions; this product replaces Pangestyme™, which is no longer manufactured.
9. Risperidone (Risperdal® equivalent) tablets – Due to generic availability, risperidone tablets are now the preferred agent for all initiation of therapy with an atypical antipsychotic. Outpatient initiation of therapy is still restricted to Psychiatry and to Dr. David Katerndahl (pending Psychiatric consult for non-urgent treatment of patients) for any psychiatric indication.
10. Sitagliptin (Januvia®) tablets - CareLink will subsidize sitagliptin pending the obtainment through a MAP and for members who do not qualify for the MAPs.



Congratulations to Susan Spencer, Reimbursement Analyst, for Pharmacoeconomics (MAP). She was named the UHS employee of the YEAR (technical category). Way to go, Susan!

Any prescriber who feels a regimen warrants special consideration, please contact:

Brandi Kelly, Pharm.D., Manager, Pharmacy Programs-CareLink at

358-3180, Brandi.Kelly@uhs-sa.com OR CareLink Authorization at 358-3224

Webform requests available at <http://www.universityhealthsystem.com/carelink/formulary-request.shtml>